Your browser doesn't support javascript.
loading
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps, Francesco; van de Kamp, Maaike W; Mayr, Roman; Bostrom, Peter J; Shariat, Shahrokh F; Hippe, Katrin; Bertz, Simone; Neuzillet, Yann; Sanders, Joyce; Otto, Wolfgang; van der Heijden, Michiel S; Jewett, Michael A S; Stöhr, Robert; Zlotta, Alexandre R; Trombetta, Carlo; Eckstein, Markus; Mertens, Laura S; Burger, Maximilian; Soorojebally, Yanish; Wullich, Bernd; Bartoletti, Riccardo; Radvanyi, François; Pavan, Nicola; Sirab, Nanour; Mir, M Carmen; Pouessel, Damien; van der Kwast, Theo H; Hartmann, Arndt; Lotan, Yair; Bussani, Rossana; Allory, Yves; van Rhijn, Bas W G.
Affiliation
  • Claps F; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • van de Kamp MW; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Mayr R; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Bostrom PJ; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Shariat SF; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Hippe K; Department of Urology, Turku University Hospital and University of Turku, Turku, Finland.
  • Bertz S; Department of Urology, University of Texas Southwestern Medical center, Dallas, TX, USA.
  • Neuzillet Y; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
  • Sanders J; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Otto W; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
  • van der Heijden MS; Department of Pathology, University Medical Center - Regensburg, Regensburg, Germany.
  • Jewett MAS; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Stöhr R; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Zlotta AR; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Trombetta C; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • Eckstein M; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Mertens LS; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Burger M; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Soorojebally Y; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Wullich B; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Bartoletti R; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
  • Radvanyi F; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Pavan N; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Sirab N; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Mir MC; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
  • Pouessel D; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • van der Kwast TH; Department of Urology & Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany.
  • Hartmann A; Unit of Urology, Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy.
  • Lotan Y; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • Bussani R; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Allory Y; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.
  • van Rhijn BWG; Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain.
BJU Int ; 132(2): 170-180, 2023 08.
Article in En | MEDLINE | ID: mdl-36748180
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Prognostic_studies Limits: Humans Language: En Journal: BJU Int Journal subject: UROLOGIA Year: 2023 Type: Article Affiliation country: Netherlands
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Prognostic_studies Limits: Humans Language: En Journal: BJU Int Journal subject: UROLOGIA Year: 2023 Type: Article Affiliation country: Netherlands